{"id":"ketoconazole-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning at application site"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL295698","moleculeType":"Small molecule","molecularWeight":"531.44"},"_dailymed":{"setId":"6f1a5365-99df-4169-9382-14c2643e561d","title":"KETOCONAZOLE (KETOCONAZOLE CREAM, 2%) CREAM [ASCLEMED USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketoconazole is an imidazole antifungal that blocks the fungal enzyme lanosterol 14α-demethylase (CYP51), a key step in ergosterol biosynthesis. Without ergosterol, the fungal cell membrane becomes unstable and permeable, leading to leakage of cellular contents and fungal cell death. The 2% formulation is typically used for topical application to treat superficial fungal infections.","oneSentence":"Ketoconazole inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis in the fungal cell membrane and causing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:46.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tinea corporis (ringworm)"},{"name":"Tinea cruris (jock itch)"},{"name":"Tinea pedis (athlete's foot)"},{"name":"Pityriasis versicolor"},{"name":"Cutaneous candidiasis"},{"name":"Seborrheic dermatitis"}]},"trialDetails":[{"nctId":"NCT07471178","phase":"PHASE4","title":"Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor","status":"NOT_YET_RECRUITING","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2026-02","conditions":"Pityriasis Versicolor","enrollment":76},{"nctId":"NCT03437005","phase":"PHASE1","title":"Alternation in the Human Microbiome With Commonly Used Topical Medications","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2013-01-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT03907046","phase":"PHASE3","title":"Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","status":"RECRUITING","sponsor":"Yale University","startDate":"2020-01-28","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation","enrollment":700},{"nctId":"NCT07333170","phase":"PHASE4","title":"Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.","status":"NOT_YET_RECRUITING","sponsor":"PAEC General Hospital, Islamabad","startDate":"2026-02","conditions":"Pityriasis Versicolor","enrollment":86},{"nctId":"NCT04869449","phase":"EARLY_PHASE1","title":"Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-11","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain","enrollment":1},{"nctId":"NCT07237763","phase":"NA","title":"Assessment of the Efficacy of Topical Ketoconazole 2% Cream in Comparison With Topical Retinoids in the Treatment of Mild Comedonal and Papulopustular Acne","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-01-15","conditions":"Acne","enrollment":52},{"nctId":"NCT02256865","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2014-10","conditions":"Insulin Resistance","enrollment":40},{"nctId":"NCT07084584","phase":"PHASE1, PHASE2","title":"An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Galecto Biotech AB","startDate":"2026-06-10","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":184},{"nctId":"NCT00859781","phase":"PHASE2","title":"177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Prostate Cancer","enrollment":55},{"nctId":"NCT05563467","phase":"PHASE2","title":"Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.","status":"RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2023-01-31","conditions":"Adrenocortical Carcinoma","enrollment":24},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":"Bacterial Vaginosis","enrollment":200},{"nctId":"NCT06170333","phase":"PHASE4","title":"8% Sulphur-Aloe Vera Soap as an Adjuvant Treatment for Pityriasis Versicolor","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2023-08-25","conditions":"Pityriasis Versicolor","enrollment":42},{"nctId":"NCT06305637","phase":"PHASE1","title":"A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-12-04","conditions":"Tinea Versicolor","enrollment":430},{"nctId":"NCT03763396","phase":"EARLY_PHASE1","title":"Azoles Targeting Recurrent High Grade Gliomas","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-06-01","conditions":"Brain Tumor, Recurrent, Cancer, Advanced, Glioma of Brain","enrollment":30},{"nctId":"NCT01154764","phase":"PHASE1","title":"Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2009-10","conditions":"Healthy","enrollment":28},{"nctId":"NCT01323465","phase":"PHASE1","title":"Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2008-02","conditions":"Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor","enrollment":36},{"nctId":"NCT05638763","phase":"PHASE2","title":"Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2024-11","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":15},{"nctId":"NCT03845348","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases","status":"UNKNOWN","sponsor":"Sao Thai Duong Joint Stock Company","startDate":"2019-05-22","conditions":"Scalp Dermatitis","enrollment":366},{"nctId":"NCT05540587","phase":"PHASE2","title":"Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis","status":"RECRUITING","sponsor":"Sung-Hwan Kim","startDate":"2022-05-20","conditions":"Mitral Valve Stenosis, Atrial Fibrillation, Stroke","enrollment":240},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT02163356","phase":"PHASE1","title":"Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma","status":"TERMINATED","sponsor":"South Plains Oncology Consortium","startDate":"2014-05","conditions":"Recurrent Neuroblastoma, Neuroblastoma","enrollment":4},{"nctId":"NCT04057950","phase":"NA","title":"Effects on the Scalp Microbiota of a 1% Selenium Disulfide and 1% Salicylic Acid Shampoo After 2% Ketaconazole Foaming Gel Treatment for Scalp Seborrheic Dermatitis","status":"COMPLETED","sponsor":"L'Oreal","startDate":"2019-06-01","conditions":"Scalp Dermatitis, Dermatitis","enrollment":80},{"nctId":"NCT00862654","phase":"PHASE3","title":"Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-03","conditions":"Scalp Seborrheic Dermatitis","enrollment":326},{"nctId":"NCT03261336","phase":"PHASE2","title":"Oral Calcitriol With Ketoconazole in CRPC","status":"TERMINATED","sponsor":"Donald Trump, MD","startDate":"2017-01-06","conditions":"Castration-resistant Prostate Cancer","enrollment":1},{"nctId":"NCT00503451","phase":"PHASE1","title":"A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-09","conditions":"Non-Hodgkin Lymphoma, Neoplasms","enrollment":14},{"nctId":"NCT00030654","phase":"PHASE3","title":"Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-10","conditions":"Prostate Cancer","enrollment":21},{"nctId":"NCT04203342","phase":"PHASE3","title":"A Therapeutic Equivalence Study of Ketoconazole Cream 2%","status":"COMPLETED","sponsor":"Douglas Pharmaceuticals America Ltd","startDate":"2019-12-11","conditions":"Tinea Pedis","enrollment":682},{"nctId":"NCT03320486","phase":"PHASE3","title":"Non-inferiority Trial of Dapaconazole Versus Ketoconazole","status":"COMPLETED","sponsor":"Biolab Sanus Farmaceutica","startDate":"2017-11-01","conditions":"Tinea Pedis","enrollment":360},{"nctId":"NCT00460031","phase":"PHASE2","title":"Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2006-09-01","conditions":"Prostate Cancer","enrollment":34},{"nctId":"NCT04212000","phase":"PHASE1","title":"Bioavailability of Levoketoconazole and Ketoconazole Tablets","status":"COMPLETED","sponsor":"Cortendo AB","startDate":"2019-12-16","conditions":"Healthy","enrollment":34},{"nctId":"NCT01576575","phase":"NA","title":"Buprenorphine Disposition and CYP3A","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-06","conditions":"Healthy","enrollment":21},{"nctId":"NCT02147964","phase":"PHASE2","title":"ITT-5 Mechanisms of Spermatogenesis in Man","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2019-06","conditions":"Gonadotropin Deficiency","enrollment":""},{"nctId":"NCT00675714","phase":"PHASE2, PHASE3","title":"Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2004-01","conditions":"Burns","enrollment":1126},{"nctId":"NCT01324310","phase":"PHASE1","title":"Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-04-01","conditions":"Hematologic Malignancy, Malignant Lymphoma","enrollment":15},{"nctId":"NCT01896323","phase":"PHASE1","title":"CC-223 and Ketoconazole Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-07-01","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT01707407","phase":"PHASE1","title":"A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-09-01","conditions":"Pharmacology, Clinical, Healthy","enrollment":32},{"nctId":"NCT04007237","phase":"PHASE4","title":"The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2018-09-01","conditions":"Pityriasis Versicolor","enrollment":100},{"nctId":"NCT03824912","phase":"PHASE3","title":"Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis","status":"COMPLETED","sponsor":"Encube Ethicals Pvt. Ltd.","startDate":"2018-08-23","conditions":"Tinea Pedis","enrollment":831},{"nctId":"NCT03688971","phase":"PHASE2","title":"Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis","status":"UNKNOWN","sponsor":"Maruho Co., Ltd.","startDate":"2018-10-22","conditions":"Seborrheic Dermatitis","enrollment":36},{"nctId":"NCT01448824","phase":"PHASE1","title":"A Study of LY2484595 on Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Healthy Participants","enrollment":82},{"nctId":"NCT01836198","phase":"PHASE1","title":"The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT03178994","phase":"PHASE3","title":"The Study of Efficacy and Safety of 2% Ketoconazole Cream in Thai Females With Mild Degree of Post - Adolescence Acne","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-08-01","conditions":"Post - Adolescence Acne","enrollment":42},{"nctId":"NCT02560051","phase":"PHASE2","title":"Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-11","conditions":"Prostatic Neoplasms","enrollment":19},{"nctId":"NCT02494713","phase":"PHASE2","title":"Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-10","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT00002855","phase":"PHASE3","title":"Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1996-08","conditions":"Prostate Cancer","enrollment":306},{"nctId":"NCT00953576","phase":"PHASE1, PHASE2","title":"Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-09-29","conditions":"Prostate Cancer","enrollment":11},{"nctId":"NCT00298155","phase":"PHASE2","title":"Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-07","conditions":"Cancer, Prostate Neoplasms","enrollment":35},{"nctId":"NCT01288521","phase":"PHASE4","title":"Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Sony Tuteja","startDate":"2008-10","conditions":"Kidney Transplantation","enrollment":8},{"nctId":"NCT00964106","phase":"PHASE1","title":"Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-26","conditions":"Drug Interactions","enrollment":87},{"nctId":"NCT00659555","phase":"PHASE1","title":"Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-04","conditions":"Macular Degeneration","enrollment":24},{"nctId":"NCT01340846","phase":"PHASE1","title":"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-03","conditions":"Cancer","enrollment":48},{"nctId":"NCT01203189","phase":"NA","title":"Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2010-09","conditions":"Seborrheic Dermatitis","enrollment":23},{"nctId":"NCT01454076","phase":"PHASE1","title":"Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2011-11-10","conditions":"Nonhematologic Malignancies, Lymphoma","enrollment":112},{"nctId":"NCT00404378","phase":"PHASE1","title":"Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-20","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":15},{"nctId":"NCT00460707","phase":"PHASE1","title":"A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":85},{"nctId":"NCT00411866","phase":"PHASE1","title":"Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-13","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT01802931","phase":"PHASE1","title":"GSK239512 DDI Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-07","conditions":"Multiple Sclerosis","enrollment":22},{"nctId":"NCT00866515","phase":"PHASE1","title":"Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12-22","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":20},{"nctId":"NCT01039974","phase":"PHASE1","title":"GSK962040 Drug-drug Interaction Study With Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-18","conditions":"Gastroparesis","enrollment":6},{"nctId":"NCT01627587","phase":"PHASE1","title":"A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-12","conditions":"Obstetric Labour, Premature","enrollment":46},{"nctId":"NCT00536991","phase":"PHASE1, PHASE2","title":"Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2006-10","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer","enrollment":51},{"nctId":"NCT01165125","phase":"PHASE1","title":"A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Asthma","enrollment":18},{"nctId":"NCT01924299","phase":"PHASE1","title":"A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT01787032","phase":"PHASE1","title":"Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT01240226","phase":"PHASE1","title":"A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Healthy Volunteer","enrollment":22},{"nctId":"NCT02606383","phase":"PHASE3","title":"Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis","status":"WITHDRAWN","sponsor":"Biolab Sanus Farmaceutica","startDate":"2016-06","conditions":"Tinea Pedis","enrollment":""},{"nctId":"NCT00703846","phase":"PHASE4","title":"STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-06","conditions":"Dermatitis, Seborrheic","enrollment":498},{"nctId":"NCT01721070","phase":"PHASE1","title":"Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2012-11","conditions":"Pharmacokinetics","enrollment":19},{"nctId":"NCT01765556","phase":"PHASE1","title":"A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-10","conditions":"Malignant Melanoma, Neoplasms","enrollment":""},{"nctId":"NCT01591850","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Healthy Volunteer","enrollment":51},{"nctId":"NCT01473316","phase":"PHASE1","title":"Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-11","conditions":"Healthy Volunteer","enrollment":22},{"nctId":"NCT01164488","phase":"PHASE1","title":"A Study of RO5190591 (Danoprevir) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT02824926","phase":"PHASE2","title":"Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis","status":"COMPLETED","sponsor":"Gilberto De Nucci","startDate":"2014-07","conditions":"Tinea Pedis","enrollment":60},{"nctId":"NCT00002760","phase":"PHASE3","title":"Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1996-08","conditions":"Prostate Cancer","enrollment":260},{"nctId":"NCT00024167","phase":"PHASE3","title":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-04","conditions":"Prostate Cancer","enrollment":265},{"nctId":"NCT00447473","phase":"PHASE2","title":"Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2006-07","conditions":"Prostatic Neoplasms","enrollment":31},{"nctId":"NCT01267084","phase":"PHASE1, PHASE2","title":"A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-02","conditions":"Neoplasm Metastases","enrollment":12},{"nctId":"NCT01476800","phase":"PHASE1","title":"A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-07","conditions":"Healthy Subjects, Pharmacokinetics of YM178","enrollment":24},{"nctId":"NCT01657838","phase":"PHASE1","title":"Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-05","conditions":"Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole, Healthy Adult Volunteers","enrollment":24},{"nctId":"NCT02068170","phase":"","title":"Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2014-02","conditions":"Delirium, QT-prolongation","enrollment":178},{"nctId":"NCT01735240","phase":"PHASE1","title":"Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-12","conditions":"Asthma,, Pharmacokinetics,, Cmax,","enrollment":15},{"nctId":"NCT00392457","phase":"NA","title":"Investigating the Regulation of Reproductive Hormones in Adult Men","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-07","conditions":"Kallmann Syndrome, Hypogonadism, Gonadal Disorder","enrollment":175},{"nctId":"NCT02198170","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-02","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT01218620","phase":"PHASE1","title":"Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09","conditions":"Adult Solid Neoplasm","enrollment":17},{"nctId":"NCT01026415","phase":"PHASE1","title":"Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2009-12","conditions":"Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic","enrollment":73},{"nctId":"NCT01679613","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Healthy","enrollment":34},{"nctId":"NCT01318265","phase":"PHASE1","title":"Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Pharmacokinetics","enrollment":24},{"nctId":"NCT02264171","phase":"PHASE1","title":"Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00824863","phase":"PHASE4","title":"Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis","status":"COMPLETED","sponsor":"Wayne Fujita, M.D.","startDate":"2008-12","conditions":"Pityrosporum Folliculitis","enrollment":10},{"nctId":"NCT02170675","phase":"PHASE1","title":"Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT00393848","phase":"PHASE2","title":"Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2006-10","conditions":"Hip Fracture, Osteoarthritis, Femur Head Necrosis","enrollment":40},{"nctId":"NCT01760642","phase":"PHASE1","title":"Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-12","conditions":"Healthy","enrollment":16},{"nctId":"NCT01259115","phase":"PHASE1","title":"Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2002-10","conditions":"Healthy","enrollment":20},{"nctId":"NCT01110330","phase":"PHASE3","title":"An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-07","conditions":"Tinea Pedis","enrollment":583},{"nctId":"NCT01405989","phase":"PHASE1","title":"To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01","conditions":"Pharmacokinetics of Darexaban and Metabolites, Healthy Subjects","enrollment":26},{"nctId":"NCT01637636","phase":"PHASE1","title":"Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2012-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT01468558","phase":"PHASE1","title":"Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT01925638","phase":"PHASE1","title":"Effect of Ketoconazole on the Pharmacokinetics of Refametinib","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09","conditions":"Drug Interactions","enrollment":18},{"nctId":"NCT00697437","phase":"PHASE2","title":"Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2006-10","conditions":"Solid Tumors","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":114,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ketoconazole 2%","genericName":"Ketoconazole 2%","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketoconazole inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis in the fungal cell membrane and causing cell death. Used for Tinea corporis (ringworm), Tinea cruris (jock itch), Tinea pedis (athlete's foot).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}